| Nine months | | Duration of initial phase of treatment |
| Four | | Analyze disease status |
| Rifampicin | | At least _____ drugs are used with multi Drug-Resistant |
| Eighteen | | Additional meds added to antibiotics for treatment of |
| HIV | | Drug used with isoniazid resistance |
| Liver toxicity | | Type of therapy initiated for chemophophylaxis of |
| Night sweats | | Granuloma with cheese-like appearance and necrotic center |
| Proliferative | | 900mg twice weekly |
| Gatifloxacin | | Coughing up blood |
| Geographic Location | | Goal of therapy |
| Male Gender | | Fluoroquinolone used in group 3 treatment |
| Four months | | Treatment period for patients with HIV infection |
| Ofloxacin | | Area of lung commonly infected upon reactivation of TB |
| Race | | Fluoroquinolone used in group 3 treatment |
| Rifampin | | Skin test using purified tuberculin protein derivative |
| Two months | | Duration of chemoprophylaxis with isoniazid resistance |
| Chest Xray | | Fluoroquinolone used in group 3 treatment |
| Alveoli | | Fluoroquinolone used in group 3 treatment |
| Six months | | Risk factor for TB infection |
| Ethambutol | | Time to develop antibodies to TB and allow a more effective |
| Hemoptysis | | Positive test in tissue or fluid specimen (three times) |
| Moxifloxacin | | First line oral antituberculosis agent |
| Macrophage | | TB is transmitter from person to person as _______ |
| Latent | | Granuloma which is stable and effectively limits the |
| AFB | | Given to reduce incidence of side effects of isoniazid |
| Amikacin | | First line oral antituberculosis agent |
| Monotherapy | | Injectable antituberculosis agent |
| INH | | First line oral antituberculosis agent |
| Three weeks | | Site of deposit of tuberculosis bacilli upon initial infection |
| Mantoux | | TB that isn't destroyed multiply in the ____ and are released |
| Pyrazinamide | | First line oral antituberculosis agent |
| Isoniazid | | Risk factor for TB infection |
| Isolation | | Constitutional symptom of TB |
| Pyridoxine | | Constitutional symptom of TB |
| Levofloxacin | | Asymptomatic infection |
| Streptomycin | | Secondary or Disseminated tuberculosis |
| Nine months | | Resurgence in the late 80's was due to ___ |
| Cipro | | Rupture of caseous liquefaction material containing mycobac |
| Droplet nuclei | | 100 fold greater risk factor for developing active TB disease |
| Steroids | | Number of months to continue treatment w/ multi drug-resistance |
| Caseating | | Nonpharmacologic means to identify where the |
| Contact investigation | | Nonpharmacologic therapy used to prevent spread of the disease |
| Apical | | Risk factor for TB infection |
| DOT Therapy | | Tuberculosis is caused by ______ |
| Miliary | | Can be discontinued once susceptibilities are available if |
| Cure | | Nonpharmacolgical therapy used to support the |
| HIV | | Best drug to use for mycobacteria within caseating |
| Reactivation Disease | | Injectable antituberculosis agent |
| Malaise | | Duration of treatment for chemoprophylaxis of HIV patients |
| Isoniazid | | Duration of treatment with only three drugs |
| Ethambutol | | Can be substituted for rifampin in HIV patients |
| Pyrazinamide | | Monitorin for chemoprophylaxis |
| Nine months | | Preferred agent for chemoprophylaxis |
| Rifabutin | | Fluoroquinolone used in group 3 treatment |
| Mycobacterium tuberculosis | | Shortest duration of treatment for chemoprophylaxis |
| Nutritional support | | Isoniazid (abbr) |
